AbbVie to Present Lung Cancer Data at WCLC 2026; ABBV-1480 Shows High Response Rates

AbbVie (NYSE: ABBV) announced new data highlighting research programs across its lung cancer portfolio being presented at the 2026 World Conference on Lung Cancer (WCLC), including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The presentations span clinical, translational and real-world data across next-generation immunotherapies and targeted antibody-drug conjugates (ADCs), designed to generate insights into treatment burden, patient experience and biomarker identification that may help inform future research.

Clinical data from AbbVie's ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in the frontline NSCLC setting will be presented via an oral presentation. AbbVie, in partnership with RemeGen, will present Phase 1b data evaluating the investigational PD-1/VEGF bispecific antibody in combination with platinum-based chemotherapy as a potential first-line treatment for advanced NSCLC. At the 10 mg/kg dose, identified as the recommended Phase 3 dose for further development in combination regimens in both squamous and non-squamous NSCLC, the primary endpoint of objective response rate (ORR) was 90.0% in squamous NSCLC (n=27/30) and 75.9% (n=22/29) in non-squamous NSCLC. The most common treatment-related adverse events (TRAEs) were a decrease in white blood cells, neutrophil, platelet counts and anemia. No grade ≥3 hemorrhages with the 10 mg combinations were observed. This overall manageable safety profile supports ongoing Phase 3 development for this novel investigational asset.

Additionally, new data and updates from AbbVie's telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and SCLC will be shared. Telisotuzumab adizutecan, an investigational c-Met-directed ADC with a topoisomerase 1 inhibitor (Top1i) payload, is being studied in a Phase 1b/2 M24-536 study (NCT06772623) evaluating a platinum-free combination of Temab-A and a PD-1 inhibitor as a potential first-line treatment for advanced non-squamous NSCLC. The study includes analyses of c-Met and PD-L1 expression to identify the patients most likely to benefit from treatment. Temab-A is also being studied in epidermal growth factor receptor (EGFR)-mutated NSCLC as monotherapy or in combination with osimertinib (NCT07155187).

ABBV-706, an investigational SEZ6-targeted ADC with a Top1i payload, is being evaluated in SCLC. As previously reported, ABBV-706 demonstrated an ORR of 82% in patients with relapsed/refractory SCLC post platinum-based chemotherapy (n=17). New safety analyses from 240 patients who received ABBV-706 monotherapy showed generally manageable hematologic and gastrointestinal toxicities, with the most common gastrointestinal events, including nausea (35.8%), vomiting (17.5%) and diarrhea (10.8%), being largely low grade and most requiring no dose adjustments. Grade ≥3 treatment-related pneumonitis or interstitial lung disease was reported in 1.7% of patients receiving ABBV-706 monotherapy. Hematologic toxicities, including anemia, neutropenia and thrombocytopenia, were among the most common TRAEs. Serious TRAEs occurred in 12.5% of patients. ABBV-706 is being evaluated as monotherapy in a Phase 3 study (NCT07365241) and in combination with atezolizumab in the Phase 2 study (NCT07155174), in SCLC.

Real-world research demonstrated that SEZ6 is broadly expressed in 91% of SCLC patients overall and in more than 96% of patients with brain or liver metastases. Research reflects AbbVie's strategy aimed at building a lung cancer pipeline spanning next-generation immunotherapies, targeted antibody-drug conjugates (ADCs) and the potential for novel combination approaches.

In other news, AbbVie outlined extensive new dermatology data to be presented at the 2026 American Academy of Dermatology meeting, including 24 abstracts across psoriatic arthritis, atopic dermatitis and psoriasis that focus on long term outcomes, safety and quality of life measures. The company announced positive Phase 1 multiple ascending dose results for ABBV-295, a long acting amylin analog in obesity, with clinically meaningful, dose dependent weight reduction over 12 to 13 weeks versus placebo. AbbVie reported that subcutaneous risankizumab induction met co-primary endpoints in the Phase 3 AFFIRM trial in moderately to severely active Crohn's disease, with higher clinical remission rates versus placebo in the induction phase. In cancer, AbbVie highlighted U.S. FDA approval of a supplemental new drug application for the all oral, fixed duration combination of VENCLEXTA and acalabrutinib in previously untreated chronic lymphocytic leukemia, supported by Phase 3 AMPLIFY data showing lower risk of disease progression or death versus chemoimmunotherapy.